Medtronic PLC $MDT Stock Position Raised by Willis Investment Counsel

Willis Investment Counsel grew its holdings in Medtronic PLC (NYSE:MDT) by 2.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 423,859 shares of the medical technology company’s stock after acquiring an additional 9,320 shares during the quarter. Medtronic accounts for approximately 1.6% of Willis Investment Counsel’s holdings, making the stock its 15th largest holding. Willis Investment Counsel’s holdings in Medtronic were worth $36,575,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of MDT. Arlington Trust Co LLC boosted its stake in Medtronic by 11.6% in the 2nd quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock worth $91,000 after purchasing an additional 120 shares in the last quarter. Bigelow Investment Advisors LLC grew its position in Medtronic by 1.1% during the 1st quarter. Bigelow Investment Advisors LLC now owns 11,125 shares of the medical technology company’s stock worth $964,000 after purchasing an additional 121 shares during the last quarter. Bank & Trust Co increased its stake in Medtronic by 2.8% during the 2nd quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock valued at $342,000 after purchasing an additional 121 shares in the last quarter. Grove Bank & Trust increased its stake in Medtronic by 1.2% during the 3rd quarter. Grove Bank & Trust now owns 10,564 shares of the medical technology company’s stock valued at $912,000 after purchasing an additional 124 shares in the last quarter. Finally, Integrity Alliance LLC. increased its stake in Medtronic by 1.7% during the 2nd quarter. Integrity Alliance LLC. now owns 7,388 shares of the medical technology company’s stock valued at $578,000 after purchasing an additional 125 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

NYSE:MDT traded up $1.69 during midday trading on Tuesday, hitting $94.46. The company’s stock had a trading volume of 1,369,843 shares, compared to its average volume of 11,428,069. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The firm’s 50 day moving average is $91.10 and its 200-day moving average is $85.05. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The firm has a market cap of $120.83 billion, a P/E ratio of 23.27, a P/E/G ratio of 2.16 and a beta of 0.55.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts anticipate that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend was Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president directly owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the transaction, the executive vice president directly owned 105,916 shares of the company’s stock, valued at approximately $10,167,936. This trade represents a 8.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,903 shares of company stock valued at $5,889,203 over the last 90 days. Insiders own 0.27% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: CE Mark expands pacemaker opportunity: Medtronic received European CE Mark approval for its Vitalis family of next-generation conduction-system pacemakers. The products are designed to support more physiologic pacing and could strengthen Medtronic’s position in the cardiac rhythm management market. Medtronic nets CE Mark for Vitalis family of conduction system pacemakers
• Positive Sentiment: Leadership and portfolio repositioning: Medtronic appointed Michael Marinaro as president with an expanded role and completed the separation of its MiniMed diabetes business following an oversubscribed exchange. The changes may allow management to focus more closely on higher-priority medical-device markets, although execution will remain important. Medtronic appoints new president and completes MiniMed spinoff
• Neutral Sentiment: Cardiac-monitoring market backdrop: A new industry forecast highlights growth in U.S. wireless cardiac monitoring through expanded reimbursement, telehealth adoption and AI-enabled wearables. The trend is favorable for Medtronic’s broader cardiac-care franchise, but the report does not represent company-specific revenue guidance. U.S. Wireless Cardiac Monitoring Systems Market forecast
• Negative Sentiment: ETF outflows and insider selling create pressure: One report estimated $94.9 million of net ETF selling in Medtronic on October 16. Separately, company executives disclosed stock sales, including a CEO transaction valued at approximately $4.75 million and another preplanned sale of 10,420 shares. Because some transactions were scheduled in advance, they may reflect portfolio planning rather than a negative view of the business, but they can weigh on sentiment. Medtronic sees net ETF selling

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research note on Wednesday, September 2nd. Truist Financial reissued a “hold” rating and set a $99.00 price objective (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Weiss Ratings raised Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday. Needham & Company LLC restated a “buy” rating on shares of Medtronic in a research note on Thursday, September 17th. Finally, Robert W. Baird lifted their price target on Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 2nd. Eighteen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.88.

About Medtronic

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.